Immucell (ICCC) Price to Sales (2010 - 2026)

Immucell (ICCC) has reported Price to Sales for 17 consecutive years, with 12.7 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales rose 30.02% year-over-year to 12.7; the trailing twelve-month figure through Jun 2026 stood at 3.41 (up 53.17% YoY), and the FY2025 full-year result was 2.01, up 15.3% from the prior year.
• Price to Sales rose to 12.7 in Q2 2026 per ICCC's latest filing, from 7.3 in the prior quarter.
• Across five years, Price to Sales topped out at 17.43 in Q2 2022 and bottomed at 5.33 in Q1 2025.
• Historically, Price to Sales has averaged 9.6 across 5 years, with a median of 10.02 in 2025.
• The sharpest annual moves came in 2024 and 2025: Price to Sales slumped 51.2% in 2024, then soared 92.51% in 2025.
• Over 5 years, Price to Sales stood at 12.08 in 2022, then tumbled by 36.56% to 7.67 in 2023, then declined by 22.17% to 5.97 in 2024, then climbed by 22.28% to 7.3 in 2025, then soared by 74.11% to 12.7 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 12.7, 7.3, and 10.27 for Q2 2026, Q4 2025, and Q3 2025 respectively.